Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ZYDUS LIFESCIENCES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ZYDUS LIFESCIENCES   ACTAVIS
EQUITY SHARE DATA
    ZYDUS LIFESCIENCES
Mar-23
ACTAVIS
Dec-18
ZYDUS LIFESCIENCES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs49516,037-   
Low Rs31910,758-   
Sales per share (Unadj.) Rs170.33,933.9-  
Earnings per share (Unadj.) Rs19.8-1,267.1-  
Cash flow per share (Unadj.) Rs26.9414.5-  
Dividends per share (Unadj.) Rs6.000-  
Avg Dividend yield %1.50-  
Book value per share (Unadj.) Rs173.016,225.6-  
Shares outstanding (eoy) m1,012.20332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.43.4 70.2%   
Avg P/E ratio x20.6-10.6 -194.7%  
P/CF ratio (eoy) x15.132.3 46.8%  
Price / Book Value ratio x2.40.8 285.0%  
Dividend payout %30.30-   
Avg Mkt Cap Rs m412,1444,456,026 9.2%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m24,5640-   
Avg. sales/employee Rs Th077,421.7-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-24,937.6-  
INCOME DATA
Net Sales Rs m172,3741,308,427 13.2%  
Other income Rs m4,74625,021 19.0%   
Total revenues Rs m177,1201,333,448 13.3%   
Gross profit Rs m29,67734,287 86.6%  
Depreciation Rs m7,227559,324 1.3%   
Interest Rs m1,29975,504 1.7%   
Profit before tax Rs m25,897-575,519 -4.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0146,780 0.0%   
Tax Rs m5,878-7,293 -80.6%   
Profit after tax Rs m20,019-421,445 -4.8%  
Gross profit margin %17.22.6 657.0%  
Effective tax rate %22.71.3 1,791.0%   
Net profit margin %11.6-32.2 -36.1%  
BALANCE SHEET DATA
Current assets Rs m100,082536,648 18.6%   
Current liabilities Rs m55,267474,737 11.6%   
Net working cap to sales %26.04.7 549.5%  
Current ratio x1.81.1 160.2%  
Inventory Days Days5020 256.8%  
Debtors Days Days9466 141.0%  
Net fixed assets Rs m144,776148,107 97.8%   
Share capital Rs m1,0120-   
"Free" reserves Rs m174,1460-   
Net worth Rs m175,1585,396,648 3.2%   
Long term debt Rs m01,900,356 0.0%   
Total assets Rs m244,9408,436,189 2.9%  
Interest coverage x20.9-6.6 -316.1%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.70.2 453.7%   
Return on assets %8.7-4.1 -212.2%  
Return on equity %11.4-7.8 -146.4%  
Return on capital %15.5-4.8 -320.7%  
Exports to sales %39.20-   
Imports to sales %11.90-   
Net fx Rs m47,0330-   
CASH FLOW
From Operations Rs m26,888467,451 5.8%  
From Investments Rs m11,712256,804 4.6%  
From Financial Activity Rs m-44,004-802,287 5.5%  
Net Cashflow Rs m-5,338-77,642 6.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 82.88 Rs / USD

Compare ZYDUS LIFESCIENCES With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ZYDUS LIFESCIENCES With: SHAMROCK IND  MERCURY LAB.  HIKAL.  PHAARMASIA  SUVEN LIFE SCIENCES  



Today's Market

Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3% Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3%(10:30 am)

Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.